



CRS 2023 #CRS2023
ANNUAL MEETING & EXPOSITION
JULY 24-28, 2023 **Paris Hotel » Las Vegas, NV, USA**
THE FUTURE OF DELIVERY SCIENCE

Innovation Showcase

Shortening development cycles
with microstructure-based
prediction of drug release

Dr. Andrew Clark
Director of Pharmaceutical Sciences
DigiM Solution
Andrew.Clark@digimsolution.com




Abstract geometric shapes in a dark blue/purple gradient: a sphere in the upper left, a cube in the middle left, and a large torus (donut shape) in the lower left.


What if we could simulate drug
release profiles, based on the
actual structures driving release?

We can! It all starts with imaging the structure in 3D...


3D FIB-SEM



3D X-ray Microscopy (X-ray micro-CT)




2D to 3D with Generative AI





Obtaining the structure provides a real input without assumptions about porosity/particle arrangement

To simulate from the imaged structure we need to classify each material domain





**Supervised
machine
learning**



**Meloxicam
particle network**

**PCL
polymer matrix**






**Applied to entire
scanned 3D structure**

With Purdue and Eli Lilly
<https://doi.org/10.1016/j.jconrel.2023.05.049>

After classification, a library of structural properties can be computed (PSD, spatial distribution, surface area, connectivity)

Lastly, we simulate drug release on the classified pixels





This simulation is on a biostable system → there are also models for biodegradable systems

With Purdue and Eli Lilly
<https://doi.org/10.1016/j.jconrel.2023.05.049>

What are the other inputs, and how does predicted release compare to *in vitro*?

External inputs for simulation:

- Bulk diffusion coefficient
- Drug load
- Drug solubility
- Diameter



Blind simulation provides highly precise prediction without any data fitting or adjustments

What are the implications?

Use of this workflow can help solve a number of the biggest challenges in controlled release development...

Accelerate Formulation Selection

Optimize Manufacturing and Scale Up

Shorten Lengthy *In Vitro* Testing

Easier Troubleshooting

Seek *In vitro-In Vivo* Correlation

Demonstrate Generic Equivalence with RLD